Literature DB >> 11917009

Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase alpha-primase.

Christian Melle1, Heinz-Peter Nasheuer.   

Abstract

The wild-type form of p53 contains an intrinsic 3'-5'-exonuclease activity. As p53 forms a complex with DNA polymerase alpha-primase (pol-prim) in vivo this finding suggests that p53 might cooperate with pol-prim to stabilize the genetic information of living cells. To test this hypothesis, exonuclease-free DNA pol-prim was expressed alone or together with p53 for purification. Pol-prim formed a complex with p53, which was purified by ion exchange and immunoaffinity chromatography from baculovirus-infected insect cells. The p53-containing pol-prim fractions removed a 3'-unpaired nucleotide with a 1.5-2-fold higher rate than a paired nucleotide, whereas the four subunit pol-prim did not have any exonuclase activity. Therefore, only p53/pol-prim was able to elongate a primer-template that contained a 3'-unpaired primer end in vitro. To achieve this, the 3'-5'-exonuclease activity of p53 excised the unpaired nucleotide at the 3'-end of the primer and created a paired 3'-end, which pol-prim was able to elongate. The exonuclease activity of p53 as well as the elongation of a primer with a mispaired 3'-end was inhibited specifically by the anti-p53 monoclonal antibodies PAb240 and PAb421.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917009      PMCID: PMC101832          DOI: 10.1093/nar/30.7.1493

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  69 in total

Review 1.  The p53 network.

Authors:  M L Agarwal; W R Taylor; M V Chernov; O B Chernova; G R Stark
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

2.  A cell-free replication system for human polyomavirus JC DNA.

Authors:  J Nesper; R W Smith; A R Kautz; E Sock; M Wegner; F Grummt; H P Nasheuer
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  p53 deficiency does not affect the accumulation of point mutations in a transgene target.

Authors:  A T Sands; M B Suraokar; A Sanchez; J E Marth; L A Donehower; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

Review 4.  Cancer cells exhibit a mutator phenotype.

Authors:  L A Loeb
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

5.  Species-specific replication of simian virus 40 DNA in vitro requires the p180 subunit of human DNA polymerase alpha-primase.

Authors:  F Stadlbauer; C Voitenleitner; A Brückner; E Fanning; H P Nasheuer
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

6.  Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein.

Authors:  P Huang
Journal:  Oncogene       Date:  1998-07-23       Impact factor: 9.867

7.  In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes.

Authors:  L Wiesmüller; J Cammenga; W W Deppert
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  14-3-3sigma is a p53-regulated inhibitor of G2/M progression.

Authors:  H Hermeking; C Lengauer; K Polyak; T C He; L Zhang; S Thiagalingam; K W Kinzler; B Vogelstein
Journal:  Mol Cell       Date:  1997-12       Impact factor: 17.970

9.  p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells.

Authors:  P A Havre; J Yuan; L Hedrick; K R Cho; P M Glazer
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

10.  p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction.

Authors:  H W Stürzbecher; B Donzelmann; W Henning; U Knippschild; S Buchhop
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

View more
  8 in total

1.  Exonucleolytic degradation of RNA by p53 protein in cytoplasm.

Authors:  Mary Bakhanashvili; Rachel Gedelovich; Shai Grinberg; Galia Rahav
Journal:  J Mol Med (Berl)       Date:  2007-08-15       Impact factor: 4.599

2.  DNA damage tolerance pathway involving DNA polymerase ι and the tumor suppressor p53 regulates DNA replication fork progression.

Authors:  Stephanie Hampp; Tina Kiessling; Kerstin Buechle; Sabrina F Mansilla; Jürgen Thomale; Melanie Rall; Jinwoo Ahn; Helmut Pospiech; Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-12       Impact factor: 11.205

3.  Alkoxylalkyl Esters of Nucleotide Analogs Inhibit Polyomavirus DNA Replication and Large T Antigen Activities.

Authors:  Nichodemus O Onwubiko; Suraya A Diaz; Marcela Krečmerová; Heinz Peter Nasheuer
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mary Bakhanashvili; Elena Novitsky; Ethan Rubinstein; Itzchak Levy; Galia Rahav
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Human cytomegalovirus primase UL70 specifically interacts with cellular factor Snapin.

Authors:  Ao Shen; Ji Lei; Edward Yang; Yonggang Pei; Yuan-Chuan Chen; Hao Gong; Gengfu Xiao; Fenyong Liu
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

Review 6.  The Tip of an Iceberg: Replication-Associated Functions of the Tumor Suppressor p53.

Authors:  Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2018-07-28       Impact factor: 6.639

Review 7.  Fidelity of DNA replication-a matter of proofreading.

Authors:  Anna Bębenek; Izabela Ziuzia-Graczyk
Journal:  Curr Genet       Date:  2018-03-02       Impact factor: 3.886

8.  SV40 T antigen helicase domain regions responsible for oligomerisation regulate Okazaki fragment synthesis initiation.

Authors:  Nichodemus O Onwubiko; Felicia Scheffel; Ingrid Tessmer; Heinz Peter Nasheuer
Journal:  FEBS Open Bio       Date:  2022-02-07       Impact factor: 2.693

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.